MEA Narcolepsy Drugs Market

MEA Narcolepsy Drugs Market Size (2022 to 2027)

The size of the Middle East and Africa narcolepsy drugs market is estimated to showcase a healthy CAGR from 2022 to 2027.

Narcolepsy can be characterized by excessive sleepiness, hallucinations, sleep paralysis, excessive daytime sleepiness, and automatic behaviors. Cataplexy, episodes of the sudden loss of muscle strength, is observed in nearly 70% of narcolepsy patients. Narcolepsy is caused by a lack of orexin, which is responsible for regulating sleep. Several other triggering factors include menopause, stress, and puberty. This disease is rare and is thought to affect more than 1 in 2,000 people. Narcolepsy with cataplexy is estimated to show a prevalence rate of 25 to 50 per 100,000 people and an incidence of 0.74 per 100,000 individuals. This disease equally affects both men and women but with a peak identification in age groups 20-40 years. Only medication and relaxation therapy are proven to improve the symptoms and lead to lifestyle changes with no permanent cure.

A person following an irregular sleep pattern and high-stress level does not achieve sound sleep, affecting his daily life. Increased awareness of sleep disorders and improved healthcare facilities to tackle this disease are the key factors that will drive the MEA narcolepsy drugs market during the upcoming years. The increased demand for advanced therapies for sleep disorders, the sustained efforts of government and non-government organizations to publicize the disease, the increase in R&D activities to find a cure for narcolepsy are the other factors expected to drive the studied market. As with other diseases characterized by selective cell loss, such as Parkinson's disease or type 1 diabetes mellitus, narcolepsy is probably caused by environmental exposures before the age of onset in genetically predisposed individuals. Researchers are studying the immune system in the development of narcolepsy for creating better drugs with lesser side effects. Therapies that modify the response of the immune system, including steroids, intravenous immunoglobulin, and plasma therapies, have been studied. Developments in the associated field will help improve the growth of the MA narcolepsy drugs market.

However, strict government regulations regarding the regulation of narcolepsy drugs are the main factor likely to hamper the market's growth during the forecast period. In addition, the harmful effects associated with anti-narcoleptic drugs, along with the potential for delays in diagnosis and treatment, are expected to hamper the market's growth. Owing to the lack of recognition among patients and healthcare providers coupled with less information and awareness will inhibit the growth of the market in the premises of the MEA region.

This research report on the Middle East and Africa narcolepsy drugs market has been segmented & sub-segmented into the following categories:

By Type: 

• Central Nervous System Stimulants
• Tricyclic Antidepressants
• Sodium Oxybate
• Selective Serotonin Reuptake Inhibitor
• Others

By Indication: 

• Daytime Extreme Sleepiness
• Cataplexia
• Others

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

In 2020, Saudi Arabia dominated the MEA market and is anticipated to continue to dominate during the forecast period. The Saudi Arabian narcolepsy drugs market is estimated to grow at a moderate CAGR, attributed to increasing awareness of the disease, unhealthy lifestyles, and a high rate of sleep apnea and obesity in the region. Moreover, increasing disposable income, adoption of advanced health care solutions for better living standards, and increased investment in the pharmaceutical and biotechnology sectors will provide the region with better growth opportunities which will, in turn, develop the MEA narcolepsy drugs market.

The United Arab Emirates is also estimated to represent a significant share of the global market due to increased R&D activities and well-established healthcare infrastructure. Additionally, advanced technology increased awareness of the diagnosis of the disease, and high health care spending is fuelling the growth of this regional market.

KEY MARKET PLAYERS:

Companies playing a notable role in the MEA narcolepsy drugs market are Ligand Pharmaceuticals, Addrenex Pharmaceuticals, Shire Plc, Teva Pharmaceutical Industries Ltd., Arena Pharmaceuticals, Jazz Pharmaceuticals Plc, Bioprojet, and Graymark Healthcare, Inc.